LUCD Lucid Diagnostics Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
Feed
04:15
Sep 13
Sep 13
Long LUCD on CMS coverage catalyst and $60B TAM
Author argues Lucid Diagnostics' EsoGuard detects precancerous Barrett's esophagus, a condition missed by MCED blood tests, with a screening population already defined by CMS and a $60B TAM based on 30M patients at the $1938 CMS price. A unanimous positive CAC meeting and expected CMS coverage decision in late 2025 or early 2026 could unlock reimbursement, with break-even at only 5-6k tests per quarter. Main stated risks are management's repeated guidance errors on CMS timing and dilution risk (cash runs out Q2 2027, but $20M ATM and VA revenue from Q4 2026 should extend runway).
HIGH
About LUCD Investor Commentary
Across the available history and selected sources, Buzzberg tracks LUCD (Lucid Diagnostics Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Past 7 days, before deduplication: 1 bullish. Latest voices: u/oaksapollo.